News >

bb2121 Continues to Show Potential in Multiple Myeloma

Jason Harris
Published: Thursday, Aug 02, 2018

Noopur Raje, MD

Noopur Raje, MD
Results from the multicenter phase I CRB-401 study evaluating the anti-BCMA chimeric antigen receptor T-cell therapy bb2121 in patients with relapsed/refractory multiple myeloma are highly encouraging, according to Noopur Raje, MD.

, Raje discussed the updated results from the CRB-401 trial and next steps with bb2121 in multiple myeloma.

OncLive: What was the rationale for CRB-401?

Raje: CAR T-cell therapy is clearly an exciting strategy not just in hematologic cancers, but a lot of solid tumors, where it is also being investigated. What we've done with the bb2121 product is use a CAR using a lentivirus vector, which recognizes a humanized BCMA. Along with that, for the costimulatory domain, we used 4-1BB. What we think is happening here is that, with the 4-1BB, we get a slow and consistent expansion of those T cells. Part of the reason for seeing less toxicity, we believe, is because of the 4-1BB costimulatory molecule.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication